SkinBioTherapeutics (SBTX) Stock Statistics & Valuation Metrics

SkinBioTherapeutics has a market cap or net worth of £53.08M. The enterprise value is 49.29M.

SkinBioTherapeutics has 258,909,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

SkinBioTherapeutics’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -7.48%.

The current PE Ratio of SkinBioTherapeutics is ―. SkinBioTherapeutics’s PEG ratio is 0.69.

In the last 12 months, SkinBioTherapeutics had revenue of 4.64M and earned -696.25K in profits. Earnings per share was 0.00.

In the last 12 months, operating cash flow was -1.30M and capital expenditures -6.30K, giving a free cash flow of -1.30M billion.

SkinBioTherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

SkinBioTherapeutics upcoming earnings date is Mar 31, 2026, TBA (Confirmed).

SkinBioTherapeutics as a current ratio of 4.84, with Debt / Equity ratio of 10.55%

In the past 12 months, SkinBioTherapeutics has paid -18.86K in taxes.

SkinBioTherapeutics EV to EBITDA ratio is -175.51, with an EV/FCF ratio of -26.45.

SkinBioTherapeutics has £4.78M in cash and marketable securities with £993.47K in debt, giving a net cash position of £3.79M billion.

Gross margin is 58.33%, with operating margin of -17.83%, and net profit margin of -15.01%.

The average price target for SkinBioTherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―